Humanized IN MATRICO™ Lung Fibrosis Assay provides insight into efficacy of drug candidates consistent with clinical results, increasing predictiveness and accelerating decision making in development of drugs for lung fibrosis.
Read MoreXylyx Bio offers advanced lung models to accelerate COVID-19-related drug development
Allevi Partners with Xylyx Bio to Create Liver Specific Bioinks
Only a handful of researchers and companies around the world are tackling liver-specific bioinks, and one of them is now Allevi. The Philadelphia-based biotech company has now partnered with Xylyx Bio, a pioneer in physiomimetic biomaterials, to introduce new tissue-specific bioinks with Decellularized Extracellular Matrix (dECM). Starting with the liver, they will seek to recapitulate the native tissue microenvironment in 3D bioprinting.
Read MoreXylyx Bio announces development of disease-specific cell culture products to accelerate anti-fibrotic drug discovery and screening
Fibrosis-specific substrates provide a disease-relevant in-vitro testing platform to inform decision-making in early-stage drug discovery. Through the development of fibrosis-specific in-vitro substrates, Xylyx Bio aims to support drug discovery and development for fibrotic diseases such as idiopathic pulmonary fibrosis (IPF) and non-alcoholic steatohepatitis (NASH).
Read MoreXylyx Bio joins Advanced Regenerative Manufacturing Institute (ARMI) Consortium
Xylyx Bio announced that it has joined the Advanced Regenerative Manufacturing Institute (ARMI), a public-private Manufacturing USA initiative that supports the manufacturing of engineered tissues and tissue-related technologies, with the goal to focus on accelerating the standardization and commercialization of tissue-specific extracellular matrix biomaterials for regenerative medicine and tissue engineering.
Read MoreXylyx Bio Announces Global Expansion
Xylyx Bio announced partnerships with 9 international distributors to meet growing demand. Additional distributors provide scientists working in drug screening, cancer research, 3D cell models and toxicology with the ability to improve the human relevance of in vitro cell models.
Read MoreEast River BioSolutions Announces Rebrand to Xylyx Bio
East River BioSolutions, a biotech company specializing in cell-specific extracellular matrix biomaterials, today announced its rebrand to Xylyx Bio. The new branding underscores the Company’s focus on accelerating science for improved human health.
Read MoreEast River BioSolutions releases NativeCoat™ ECM substrates
East River BioSolutions announced the release of NativeCoat™ ECM – a novel line of 2D in vitro cell culture coatings comprised of native tissue-derived extracellular matrix (ECM) that enables scientists to study cells in their tissue-specific microenvironments, leading to more physiologically relevant testing and thus more accurate and actionable scientific results.
Read MoreEast River BioSolutions Awarded NIH SBIR Phase I Grant
East River BioSolutions is proud to announce that it has been awarded SBIR Phase I grant from the NIIH. The award will support further development of a fibrotic lung-specific cell culture substrate that will allow scientists to build more physiologically relevant in vitro models of IPF.
Read More